Receptos’s “Buy” Rating Reaffirmed at Wedbush (RCPT)
Receptos (NASDAQ:RCPT)‘s stock had its “buy” rating reiterated by equities researchers at Wedbush in a research report issued on Wednesday, Analyst Ratings.Net reports. They currently have a $19.39 price objective on the stock. Wedbush’s price target would indicate a potential downside of 28.19% from the company’s current price.
Shares of Receptos (NASDAQ:RCPT) traded up 25.46% during mid-day trading on Wednesday, hitting $33.875. 1,568,150 shares of the company’s stock traded hands. Receptos has a one year low of $13.00 and a one year high of $31.82. The stock has a 50-day moving average of $23.31 and a 200-day moving average of $19.39.
Separately, analysts at BMO Capital Markets raised their price target on shares of Receptos to $40.00 in a research note to investors on Wednesday.
Receptos, Inc (NASDAQ:RCPT) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.